Limitations in anti-obesity drug development: The critical role of hunger-promoting neurons

Nature Reviews Drug Discovery

Volumn 11, Issue 9, 2012, Pages 675-691

  Dietrich, Marcelo O ^a,b   Horvath, Tamas L ^a  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b FEDERAL UNIVERSITY OF RIO GRANDE DO SUL   (Brazil)

Author keywords

[No Author keywords available]

Indexed keywords

AMFEBUTAMONE; AMFEBUTAMONE PLUS NALTREXONE; AMFEPRAMONE; ANTIOBESITY AGENT; BENZPHETAMINE; CETILISTAT; DEXFENFLURAMINE; ENZYME INHIBITOR; FENFLURAMINE; GHRELIN; LORCASERIN; METFORMIN; METHIONYL AMINOPEPTIDASE 2 INHIBITOR; NALTREXONE; PHENDIMETRAZINE; PHENTERMINE; PHENTERMINE PLUS TOPIRAMATE; PLACEBO; QSYMIA; RESVERATROL; RIMONABANT; SIBUTRAMINE; SULFONYLUREA; TARANABANT; TETRAHYDROLIPSTATIN; TOPIRAMATE; UNCLASSIFIED DRUG;

APPETITE; ATTENTION; BICARBONATE BLOOD LEVEL; BRAIN FUNCTION; BRAIN NERVE CELL; CALORIC RESTRICTION; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CENTRAL NERVOUS SYSTEM; CONSTIPATION; DEPRESSION; DIZZINESS; DRUG DEVELOPMENT; DRUG MECHANISM; ENVIRONMENT; EPILEPSY; EXERCISE; FECES INCONTINENCE; FLATULENCE; FOOD INTAKE; GASTROINTESTINAL SYMPTOM; HALLUCINATION; HEADACHE; HORMONE RELEASE; HUMAN; HYPERTENSION; HYPOTHALAMUS; INSOMNIA; KIDNEY INJURY; LIVER INJURY; MALABSORPTION; MEMORY; MENTAL CONCENTRATION; MENTAL DISEASE; METABOLIC DISORDER; MIGRAINE; MOOD CHANGE; NAUSEA; NEPHROLITHIASIS; NERVOUSNESS; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OBESITY; PARESTHESIA; POTASSIUM BLOOD LEVEL; PRIORITY JOURNAL; PSYCHOMOTOR DISORDER; PULMONARY HYPERTENSION; RESTLESSNESS; REVIEW; RISK; RISK BENEFIT ANALYSIS; SEXUAL BEHAVIOR; SIDE EFFECT; STEATORRHEA; SUICIDE RISK; TACHYCARDIA; TASTE DISORDER; UNSPECIFIED SIDE EFFECT; VALVULAR HEART DISEASE; VOMITING; XEROSTOMIA;

ANIMALS; ANTI-OBESITY AGENTS; APPETITE; DRUG DISCOVERY; EATING; HUMANS; HUNGER; NEURONS; OBESITY;

EID: 84866108680     PISSN: 14741776     EISSN: 14741784     Source Type: Journal    
DOI: 10.1038/nrd3739     Document Type: Review

References (265)

1. Finucane, M. M. et al. National, regional, and global trends in body-mass index since 1980: systematic analysis of health examination surveys and epidemiological studies with 960 country-years and 9.1 million participants. Lancet 377, 557-567 (2011).
2. Ioannides-Demos, L. L., Piccenna, L. & McNeil, J. J. Pharmacotherapies for obesity: past, current, and future therapies. J. Obes. 2 011, 179674 (2011).
3. Jones, D. Suspense builds on anti-obesity rollercoaster ride. Nature Rev. Drug Discov. 10, 5-6 (2011).
4. Huntington, M. K. & Shewmake, R. A. Anti-obesity drugs: are they worth it? Future Med. Chem. 3, 267-269 (2011).
5. Powell, A. G., Apovian, C. M. & Aronne, L. J. New drug targets for the treatment of obesity. Clin. Pharmacol. Ther. 90, 40-51 (2011).
6. Ben-Dor, M., Gopher, A., Hershkovitz, I. & Barkai, R. Man the fat hunter: the demise of Homo erectus and the emergence of a new hominin lineage in the Middle Pleistocene (ca. 400 kyr) Levant. PLoS ONE 6, e28689 (2011).
7. Eaton, S. B. & Konner, M. Paleolithic nutrition. A consideration of its nature and current implications. N. Engl. J. Med. 312, 283-289 (1985).
8. Leonard, W. R. Food for thought. Dietary change was a driving force in human evolution. Sci. Am. 287, 106-115 (2002).
9. Thompson, R. F. The neurobiology of learning and memory. Science 233, 941-947 (1986).
10. Seeley, R. J. & Woods, S. C. Monitoring of stored and available fuel by the CNS: implications for obesity. Nature Rev. Neurosci. 4, 901-909 (2003).
11. Cone, R. Studies on the physiological functions of the melanocortin system. Endocr. Rev. 27, 736-749 (2006).
12. Gao, Q. & Horvath, T. L. Neurobiology of feeding and energy expenditure. Annu. Rev. Neurosci. 30, 367-398 (2007).
13. Fontana, L. Modulating human aging and age-associated diseases. Biochim. Biophys. Acta 1790, 1133-1138 (2009).
14. Piper, M. D. W. & Bartke, A. Diet and aging. Cell Metab. 8, 99-104 (2008).
15. Fontana, L., Partridge, L. & Longo, V. D. Extending healthy life span\from yeast to humans. Science 328, 321-326 (2010).
16. Hetherington, A. W. & Ranson, S. W. Hypothalamic lesions and adiposity in the rat. Anat. Rec. 78, 149-172 (1940).
17. Hetherington, A. W. & Ranson, S. W. The relation of various hypothalamic lesions to adiposity in the rat. J. Comp. Neurol. 76, 475-499 (1942).
18. Hetherington, A. W. Non-production of hypothalamic obesity in the rat by lesions rostral or dorsal to the ventro-medial hypothalamic nuclei. J. Comp. Neurol. 80, 33-45 (1944).
19. Anand, B. K. & Brobeck, J. R. Hypothalamic control of food intake in rats and cats. Yale J. Biol. Med. 24, 123-140 (1951).
20. Anand, B. K. & Brobeck, J. R. Localization of a "feeding center" in the hypothalamus of the rat. Proc. Soc. Exp. Biol. Med. 77, 323-324 (1951).
21. De Lecea, L. et al. The hypocretins: hypothalamus-specific peptides with neuroexcitatory activity. Proc. Natl Acad. Sci. USA 95, 322-327 (1998).
22. Sakurai, T. et al. Orexins and orexin receptors: a family of hypothalamic neuropeptides and G protein-coupled receptors that regulate feeding behavior. Cell 92, 573-585 (1998).
23. Qu, D. Q. et al. A role for melanin-concentrating hormone in the central regulation of feeding behaviour. Nature 380, 243-247 (1996).
24. Olney, J. W. Brain lesions, obesity, and other disturbances in mice treated with monosodium glutamate. Science 164, 719-721 (1969).
25. Luquet, S., Perez, F., Hnasko, T. & Palmiter, R. NPY/AgRP neurons are essential for feeding in adult mice but can be ablated in neonates. Science 310, 683-685 (2005).
26. Wu, Q., Boyle, M. & Palmiter, R. Loss of GABAergic signaling by AgRP neurons to the parabrachial nucleus leads to starvation. Cell 137, 1225-1234 (2009).
27. Gropp, E. et al. Agouti-related peptide-expressing neurons are mandatory for feeding. Nature Neurosci. 8, 1289-1291 (2005).
28. Bewick, G. et al. Post-embryonic ablation of AgRP neurons in mice leads to a lean, hypophagic phenotype. FASEB J. 19, 1680-1682 (2005).
29. Dietrich, M. O. & Horvath, T. L. GABA keeps up an appetite for life. Cell 137, 1177-1179 (2009).
30. Hahn, T., Breininger, J., Baskin, D. & Schwartz, M. Coexpression of Agrp and NPY in fasting-activated hypothalamic neurons. Nature Neurosci. 1, 271-272 (1998).
31. Horvath, T., Naftolin, F., Kalra, S. & Leranth, C. Neuropeptide-Y innervation of β-endorphin-containing cells in the rat mediobasal hypothalamus: a light and electron microscopic double immunostaining analysis. Endocrinology 131, 2461-2467 (1992).
32. Horvath, T. L., Bechmann, I., Naftolin, F., Kalra, S. P. & Leranth, C. Heterogeneity in the neuropeptide Y-containing neurons of the rat arcuate nucleus: GABAergic and non-GABAergic subpopulations. Brain Res. 756, 283-286 (1997).
33. Clark, J. T., Kalra, P. S., Crowley, W. R. & Kalra, S. P. Neuropeptide-Y and human pancreatic-polypeptide stimulate feeding-behavior in rats. Endocrinology 115, 427-429 (1984).
34. Cowley, M. et al. Leptin activates anorexigenic POMC neurons through a neural network in the arcuate nucleus. Nature 411, 480-484 (2001).
35. Pinto, S. et al. Rapid rewiring of arcuate nucleus feeding circuits by leptin. Science 304, 110-115 (2004).
36. Ollmann, M. M. et al. Antagonism of central melanocortin receptors in vitro and in vivo by Agouti-related protein. Science 278, 135-138 (1997).
37. Qian, S. et al. Neither agouti-related protein nor neuropeptide Y is critically required for the regulation of energy homeostasis in mice. Mol. Cell. Biol. 22, 5027-5035 (2002).
38. Wu, Q., Howell, M. P. & Palmiter, R. D. Ablation of neurons expressing agouti-related protein activates Fos and gliosis in postsynaptic target regions. J. Neurosci. 28, 9218-9226 (2008).
39. Zhang, Y. et al. Positional cloning of the mouse obese gene and its human homologue. Nature 372, 425-432 (1994).
40. Halaas, J. L. et al. Weight-reducing effects of the plasma protein encoded by the obese gene. Science 269, 543-546 (1995).
41. Farooqi, I. S. Genetic aspects of severe childhood obesity. Pediatr. Endocrinol. Rev. 3 (Suppl. 4), 528-536 (2006).
42. Farooqi, I. S. Monogenic human obesity syndromes. Prog. Brain Res. 153, 119-125 (2006).
43. Farooqi, I. S. et al. Clinical and molecular genetic spectrum of congenital deficiency of the leptin receptor. N. Engl. J. Med. 356, 237-247 (2007).
44. Hummel, K. P., Dickie, M. M. & Coleman, D. L. Diabetes, a new mutation in the mouse. Science 153, 1127-1128 (1966).
45. Tartaglia, L. A. et al. Identification and expression cloning of a leptin receptor, OB-R. Cell 83, 1263-1271 (1995).
46. Chen, H. et al. Evidence that the diabetes gene encodes the leptin receptor: identification of a mutation in the leptin receptor gene in db/db mice. Cell 84, 491-495 (1996).
47. Montague, C. T. et al. Congenital leptin deficiency is associated with severe early-onset obesity in humans. Nature 387, 903-908 (1997).
48. Farooqi, I. S. et al. Effects of recombinant leptin therapy in a child with congenital leptin deficiency. N. Engl. J. Med. 341, 879-884 (1999).
49. Considine, R. V. et al. Serum immunoreactive-leptin concentrations in normal-weight and obese humans. N. Engl. J. Med. 334, 292-295 (1996).
50. Maffei, M. et al. Leptin levels in human and rodent: measurement of plasma leptin and ob RNA in obese and weight-reduced subjects. Nature Med. 1, 1155-1161 (1995).
51. Halaas, J. L. et al. Physiological response to long-term peripheral and central leptin infusion in lean and obese mice. Proc. Natl Acad. Sci. USA 94, 8878-8883 (1997).
52. Cusin, I., Rohner-Jeanrenaud, F., Stricker-Krongrad, A. & Jeanrenaud, B. The weight-reducing effect of an intracerebroventricular bolus injection of leptin in genetically obese fa/fa rats. Reduced sensitivity compared with lean animals. Diabetes 45, 1446-1450 (1996).
53. Vaisse, C. et al. Leptin activation of Stat3 in the hypothalamus of wild-type and ob/ob mice but not db/db mice. Nature Genet. 14, 95-97 (1996).
54. Cone, R. D. Anatomy and regulation of the central melanocortin system. Nature Neurosci. 8, 571-578 (2005).
55. Ozcan, L. et al. Endoplasmic reticulum stress plays a central role in development of leptin resistance. Cell Metab. 9, 35-51 (2009).
56. Ozcan, U. et al. Endoplasmic reticulum stress links obesity, insulin action, and type 2 diabetes. Science 306, 457-461 (2004).
57. Ozcan, U. et al. Chemical chaperones reduce ER stress and restore glucose homeostasis in a mouse model of type 2 diabetes. Science 313, 1137-1140 (2006).
58. Diano, S. et al. Peroxisome proliferation-associated control of reactive oxygen species sets melanocortin tone and feeding in diet-induced obesity. Nature Med. 17, 1121-1127 (2011).
59. Toro, A. A. et al. Pex3p-dependent peroxisomal biogenesis initiates in the endoplasmic reticulum of human fibroblasts. J. Cell Biochem. 107, 1083-1096 (2009).
60. Titorenko, V. I. & Mullen, R. T. Peroxisome biogenesis: the peroxisomal endomembrane system and the role of the ER. J. Cell Biol. 174, 11-17 (2006).
61. Schluter, A. et al. The evolutionary origin of peroxisomes: an ER-peroxisome connection. Mol. Biol. Evol. 23, 838-845 (2006).
62. Andrews, Z. B. et al. UCP2 mediates ghrelin's action on NPY/AgRP neurons by lowering free radicals. Nature 454, 846-851 (2008).
63. Horvath, T. L., Andrews, Z. B. & Diano, S. Fuel utilization by hypothalamic neurons: roles for ROS. Trends Endocrinol. Metab. 20, 78-87 (2009).
64. Horvath, T. L. et al. Synaptic input organization of the melanocortin system predicts diet-induced hypothalamic reactive gliosis and obesity. Proc. Natl Acad. Sci. USA 107, 14875-14880 (2010).
65. Thaler, J. P. et al. Obesity is associated with hypothalamic injury in rodents and humans. J. Clin. Invest. 122, 153-162 (2012).
66. Cruickshank, C. C. & Dyer, K. R. A review of the clinical pharmacology of methamphetamine. Addiction 104, 1085-1099 (2009).
67. Frohmader, K. S., Pitchers, K. K., Balfour, M. E. & Coolen, L. M. Mixing pleasures: review of the effects of drugs on sex behavior in humans and animal models. Horm. Behav. 58, 149-162 (2010).
68. Garfield, A. S. & Heisler, L. K. Pharmacological targeting of the serotonergic system for the treatment of obesity. J. Physiol. 587, 49-60 (2009).
69. Saller, C. F. & Stricker, E. M. Hyperphagia and increased growth in rats after intraventricular injection of 5,7-dihydroxytryptamine. Science 192, 385-387 (1976).
70. Fletcher, P. J. & Paterson, I. A. A comparison of the effects of tryptamine and 5-hydroxytryptamine on feeding following injection into the paraventricular nucleus of the hypothalamus. Pharmacol. Biochem. Behav. 32, 907-911 (1989).
71. Heisler, L. K. et al. Activation of central melanocortin pathways by fenfluramine. Science 297, 609-611 (2002).
72. Choi, S., Blake, V., Cole, S. & Fernstrom, J. D. Effects of chronic fenfluramine administration on hypothalamic neuropeptide mRNA expression. Brain Res. 1087, 83-86 (2006).
73. Heisler, L. K. et al. Serotonin reciprocally regulates melanocortin neurons to modulate food intake. Neuron 51, 239-249 (2006).
74. 2C receptor agonist promotes hypophagia via downstream activation of melanocortin 4 receptors. Endocrinology 149, 1323-1328 (2008).
75. Guerciolini, R. Mode of action of orlistat. Int. J. Obes. Relat. Metab. Disord. 21 (Suppl. 3), 12-23 (1997).
76. Hartmann, D., Hussain, Y., Guzelhan, C. & Odink, J. Effect on dietary fat absorption of orlistat, administered at different times relative to meal intake. Br. J. Clin. Pharmacol. 36, 266-270 (1993).
77. Drent, M. L. et al. Orlistat (Ro 18-0647), a lipase inhibitor, in the treatment of human obesity: a multiple dose study. Int. J. Obes. Relat. Metab. Disord. 19, 221-226 (1995).
78. James, W. P., Avenell, A., Broom, J. & Whitehead, J. A one-year trial to assess the value of orlistat in the management of obesity. Int. J. Obes. Relat. Metab. Disord. 21 (Suppl. 3), 24-30 (1997).
79. Padwal, R. Cetilistat, a new lipase inhibitor for the treatment of obesity. Curr. Opin. Investig. Drugs 9, 414-421 (2008).
80. Yamada, Y., Kato, T., Ogino, H., Ashina, S. & Kato, K. Cetilistat (ATL-962), a novel pancreatic lipase inhibitor, ameliorates body weight gain and improves lipid profiles in rats. Horm. Metab. Res. 40, 539-543 (2008).
81. Kopelman, P. et al. Cetilistat (ATL-962), a novel lipase inhibitor: a 12-week randomized, placebo-controlled study of weight reduction in obese patients. Int. J. Obes. (Lond.) 31, 494-499 (2007).
82. Bryson, A., de la Motte, S. & Dunk, C. Reduction of dietary fat absorption by the novel gastrointestinal lipase inhibitor cetilistat in healthy volunteers. Br. J. Clin. Pharmacol. 67, 309-315 (2009).
83. Kopelman, P. et al. Weight loss, HbA1c reduction, and tolerability of cetilistat in a randomized, placebo-controlled phase 2 trial in obese diabetics: comparison with orlistat (Xenical). Obesity (Silver Spring) 18, 108-115 (2010).
84. Hollander, P. A. et al. Role of orlistat in the treatment of obese patients with type 2 diabetes. A 1-year randomized double-blind study. Diabetes Care 21, 1288-1294 (1998).
85. Heymsfield, S. B. et al. Effects of weight loss with orlistat on glucose tolerance and progression to type 2 diabetes in obese adults. Arch. Intern. Med. 160, 1321-1326 (2000).
86. Kelley, D. E. et al. Clinical efficacy of orlistat therapy in overweight and obese patients with insulin-treated type 2 diabetes: a 1-year randomized controlled trial. Diabetes Care 25, 1033-1041 (2002).
87. Miles, J. M. et al. Effect of orlistat in overweight and obese patients with type 2 diabetes treated with metformin. Diabetes Care 25, 1123-1128 (2002).
88. Hanefeld, M. & Sachse, G. The effects of orlistat on body weight and glycaemic control in overweight patients with type 2 diabetes: a randomized, placebo-controlled trial. Diabetes Obes. Metab. 4, 415-423 (2002).
89. Guy-Grand, B. et al. International trial of long-term dexfenfluramine in obesity. Lancet 2, 1142-1145 (1989).
90. Mathus-Vliegen, E. M., van de Voorde, K., Kok, A. M. & Res, A. M. Dexfenfluramine in the treatment of severe obesity: a placebo-controlled investigation of the effects on weight loss, cardiovascular risk factors, food intake and eating behaviour. J. Intern. Med. 232, 119-127 (1992).
91. Jick, H. et al. A population-based study of appetite-suppressant drugs and the risk of cardiac-valve regurgitation. N. Engl. J. Med. 339, 719-724 (1998).
92. Loke, Y. K., Derry, S. & Pritchard-Copley, A. Appetite suppressants and valvular heart disease\a systematic review. BMC Clin. Pharmacol. 2, 6 (2002).
93. Abenhaim, L. et al. Appetite-suppressant drugs and the risk of primary pulmonary hypertension. International Primary Pulmonary Hypertension Study Group. N. Engl. J. Med. 335, 609-616 (1996).
94. Devereux, R. B. Appetite suppressants and valvular heart disease. N. Engl. J. Med. 339, 765-766 (1998).
95. Centers for Disease Control and Prevention. Cardiac valvulopathy associated with exposure to fenfluramine or dexfenfluramine: US Department of Health and Human Services interim public health recommendations, November 1997. JAMA 278, 1729-1731 (1997).
96. Delcroix, M., Kurz, X., Walckiers, D., Demedts, M. & Naeije, R. High incidence of primary pulmonary hypertension associated with appetite suppressants in Belgium. Eur. Respir. J. 12, 271-276 (1998).
97. Weintraub, M., Rubio, A., Golik, A., Byrne, L. & Scheinbaum, M. L. Sibutramine in weight control: a dose-ranging, efficacy study. Clin. Pharmacol. Ther. 50, 330-337 (1991).
98. Bray, G. A. et al. A double-blind randomized placebo-controlled trial of sibutramine. Obes. Res. 4, 263-270 (1996).
99. Rolls, B. J., Shide, D. J., Thorwart, M. L. & Ulbrecht, J. S. Sibutramine reduces food intake in non-dieting women with obesity. Obes. Res. 6, 1-11 (1998).
100. Seagle, H. M., Bessesen, D. H. & Hill, J. O. Effects of sibutramine on resting metabolic rate and weight loss in overweight women. Obes. Res. 6, 115-121 (1998).
101. Hanotin, C., Thomas, F., Jones, S. P., Leutenegger, E. & Drouin, P. A comparison of sibutramine and dexfenfluramine in the treatment of obesity. Obes. Res. 6, 285-291 (1998).
102. Bray, G. A. et al. Sibutramine produces dose-related weight loss. Obes. Res. 7, 189-198 (1999).
103. Tambascia, M. A. et al. Sibutramine enhances insulin sensitivity ameliorating metabolic parameters in a double-blind, randomized, placebo-controlled trial. Diabetes Obes. Metab. 5, 338-344 (2003).
104. Sanchez-Reyes, L. et al. Use of sibutramine in overweight adult hispanic patients with type 2 diabetes mellitus: a 12-month, randomized, double-blind, placebo-controlled clinical trial. Clin. Ther. 26, 1427-1435 (2004).
105. Garcia-Morales, L. M. et al. Use of sibutramine in obese mexican adolescents: a 6-month, randomized, double-blind, placebo-controlled, parallel-group trial. Clin. Ther. 28, 770-782 (2006).
106. Lindholm, A. et al. Effect of sibutramine on weight reduction in women with polycystic ovary syndrome: a randomized, double-blind, placebo-controlled trial. Fertil. Steril. 89, 1221-1228 (2008).
107. Cota, D. et al. The endogenous cannabinoid system affects energy balance via central orexigenic drive and peripheral lipogenesis. J. Clin. Invest. 112, 423-431 (2003).
108. Addy, C. et al. The acyclic CB1R inverse agonist taranabant mediates weight loss by increasing energy expenditure and decreasing caloric intake. Cell Metab. 7, 68-78 (2008).
109. Rinaldi-Carmona, M. et al. SR141716A, a potent and selective antagonist of the brain cannabinoid receptor. FEBS Lett. 350, 141240-141244 (1994).
110. Rinaldi-Carmona, M. et al. Biochemical and pharmacological characterisation of SR141716A, the first potent and selective brain cannabinoid receptor antagonist. Life Sci. 56, 141941-141947 (1995).
111. Després, J.-P. et al. Effects of rimonabant on metabolic risk factors in overweight patients with dyslipidemia. N. Engl. J. Med. 353, 2121-2134 (2005).
112. Van Gaal, L. F. et al. Effects of the cannabinoid-1 receptor blocker rimonabant on weight reduction and cardiovascular risk factors in overweight patients: 1-year experience from the RIO-Europe study. Lancet 365, 1389-1397 (2005).
113. Pi-Sunyer, F. X. et al. Effect of rimonabant, a cannabinoid-1 receptor blocker, on weight and cardiometabolic risk factors in overweight or obese patients: RIO-North America: a randomized controlled trial. JAMA 295, 761-775 (2006).
114. Curioni, C. & André, C. Rimonabant for overweight or obesity. Cochrane Database Syst. Rev. CD006162 (2006).
115. Christensen, R., Kristensen, P. K., Bartels, E. M., Bliddal, H. & Astrup, A. Efficacy and safety of the weight-loss drug rimonabant: a meta-analysis of randomised trials. Lancet 370, 1706-1713 (2007).
116. Nathan, P. J., O'Neill, B. V., Napolitano, A. & Bullmore, E. T. Neuropsychiatric adverse effects of centrally acting antiobesity drugs. CNS Neurosci. Ther. 17, 490-505 (2010).
117. Addy, C. et al. Multiple-dose pharmacokinetics, pharmacodynamics, and safety of taranabant, a novel selective cannabinoid-1 receptor inverse agonist, in healthy male volunteers. J. Clin. Pharmacol. 48, 734-744 (2008).
118. Addy, C. et al. Safety, tolerability, pharmacokinetics, and pharmacodynamic properties of taranabant, a novel selective cannabinoid-1 receptor inverse agonist, for the treatment of obesity: results from a double-blind, placebo-controlled, single oral dose study in healthy volunteers. J. Clin. Pharmacol. 48, 418-427 (2008).
119. Wadden, T. A. et al. A randomized trial of lifestyle modification and taranabant for maintaining weight loss achieved with a low-calorie diet. Obesity (Silver Spring) 18, 2301-2310 (2010).
120. Proietto, J. et al. A clinical trial assessing the safety and efficacy of the CB1R inverse agonist taranabant in obese and overweight patients: low-dose study. Int. J. Obes. (Lond.) 34, 1243-1254 (2010).
121. Kipnes, M. S. et al. A one-year study to assess the safety and efficacy of the CB1R inverse agonist taranabant in overweight and obese patients with type 2 diabetes. Diabetes Obes. Metab. 12, 517-531 (2010).
122. Aronne, L. J. et al. A clinical trial assessing the safety and efficacy of taranabant, a CB1R inverse agonist, in obese and overweight patients: a high-dose study. Int. J. Obes. (Lond.) 34, 919-935 (2010).
123. Koch, L. Obesity: taranabant no longer developed as an antiobesity agent. Nature Rev. Endocrinol. 6, 300 (2010).
124. Griffith, D. A. et al. Discovery of 1-[9-(4-chlorophenyl)-8-(2- chlorophenyl)-9H-purin-6-yl]-4-ethylaminopip-eridine-4-carboxylic acid amide hydrochloride (CP-945598), a novel, potent, and selective cannabinoid type 1 receptor antagonist. J. Med. Chem. 52, 234-237 (2009).
125. 1 receptor antagonist for the management of obesity. Biochem. Biophys. Res. Commun. 394, 366-371 (2010).
126. 1 receptor antagonist, on weight loss and maintenance. Obesity 19, 1404-1414 (2011).
127. 1 antagonism provides food intake-independent metabolic benefits in diet-induced obese rats. Diabetes 57, 2977-2991 (2008).
128. 1 receptors in adiposity control. Int. J. Obes. (Lond.) 34, 547-556 (2010).
129. Quarta, C., Mazza, R., Obici, S., Pasquali, R. & Pagotto, U. Energy balance regulation by endocannabinoids at central and peripheral levels. Trends Mol. Med. 17, 518-526 (2011).
130. Heisler, L. K. et al. Central serotonin and melanocortin pathways regulating energy homeostasis. Ann. NY Acad. Sci. 994, 169-174 (2003).
131. 2C receptor agonist for the treatment of obesity. J. Med. Chem. 51, 305-313 (2008).
132. Thomsen, W. J. et al. Lorcaserin, a novel selective human 5-hydroxytryptamine2C agonist: in vitro and in vivo pharmacological characterization. J. Pharmacol. Exp. Ther. 325, 577-587 (2008).
133. Smith, S. R. et al. Multicenter, placebo-controlled trial of lorcaserin for weight management. N. Engl. J. Med. 363, 245-256 (2010).
134. Fidler, M. C. et al. A one-year randomized trial of lorcaserin for weight loss in obese and overweight adults: the BLOSSOM trial. J. Clin. Endocrinol. Metab. 96, 3067-3077 (2011).
135. Arena Pharmaceuticals. Lorcaserin Phase 3 Clinical Trial in Patients with Type 2 Diabetes Shows Statistically Significant Weight Loss. Arena Pharmaceuticals [online], http://invest.arenapharm.com/releasedetail.cfm? releaseid=528113 (2010).
136. O'Neil, P. M. et al. Randomized placebo-controlled clinical trial of lorcaserin for weight loss in type 2 diabetes mellitus: the BLOOM-DM study. Obesity (Silver Spring) 16 Mar 2012 (doi:10.1038/oby.2012.66).
137. 2C receptor protein in the rat CNS. Neuropharmacology 39, 123-132 (2000).
138. Abramowski, D., Rigo, M., Duc, D., Hoyer, D. & Staufenbiel, M. Localization of the 5-hydroxytryptamine 2C receptor protein in human and rat brain using specific antisera. Neuropharmacology 34, 1635-1645 (1995).
139. Abramowski, D. & Staufenbiel, M. Identification of the 5-hydroxytryptamine 2C receptor as a 60-kDa N-glycosylated protein in choroid plexus and hippocampus. J. Neurochem. 65, 782-790 (1995).
140. Sharma, A., Punhani, T. & Fone, K. C. Distribution of the 5-hydroxytryptamine 2C receptor protein in adult rat brain and spinal cord determined using a receptor-directed antibody: effect of 5,7- dihydroxytryptamine. Synapse 27, 45-56 (1997).
141. Pollack, A. Panel recommends more testing for obesity drugs. The New York Times [online], http://www. nytimes.com/2012/03/30/health/panel-recommends- more-testing-for-obesity-drugs.html (2012).
142. Ledford, H. Heart studies needed for obesity drugs, FDA advisers say. Nature [online], http://blogs.nature. com/news/2012/03/heart-studies-needed-for- obesity-drugs-fda-advisers-say.html (2012).
143. Gadde, K. M. et al. Bupropion for weight loss: an investigation of efficacy and tolerability in overweight and obese women. Obes. Res. 9, 544-551 (2001).
144. Anderson, J. W. et al. Bupropion SR enhances weight loss: a 48-week double-blind, placebo-controlled trial. Obes. Res. 10, 633-641 (2002).
145. Greenway, F. L. et al. Rational design of a combination medication for the treatment of obesity. Obesity 17, 30-39 (2009).
146. Wellman, P. J. Norepinephrine and the control of food intake. Nutrition 16, 837-842 (2000).
147. Hnasko, T. S., Szczypka, M. S., Alaynick, W. A., During, M. J. & Palmiter, R. D. A role for dopamine in feeding responses produced by orexigenic agents. Brain Res. 1023, 309-318 (2004).
148. Sotak, B. N., Hnasko, T. S., Robinson, S., Kremer, E. J. & Palmiter, R. D. Dysregulation of dopamine signaling in the dorsal striatum inhibits feeding. Brain Res. 1061, 88-96 (2005).
149. Hnasko, T. S. et al. Cre recombinase-mediated restoration of nigrostriatal dopamine in dopamine-deficient mice reverses hypophagia and bradykinesia. Proc. Natl Acad. Sci. USA 103, 8858-8863 (2006).
150. Domingos, A. I. et al. Leptin regulates the reward value of nutrient. Nature Neurosci. 14, 1562-1568 (2011).
151. Ornellas, T. & Chavez, B. Naltrexone SR/Bupropion SR (Contrave): a new approach to weight loss in obese adults. P T 36, 255-262 (2011).
152. Wadden, T. A. et al. Weight loss with naltrexone SR/bupropion SR combination therapy as an adjunct to behavior modification: the COR-BMOD trial. Obesity 19, 110-120 (2011).
153. Greenway, F. L. et al. Effect of naltrexone plus bupropion on weight loss in overweight and obese adults (COR-I): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. Lancet 376, 595-605 (2010).
154. Orexigen Therapeutics. Orexigen and FDA Identify a Clear and Feasible Path to Approval for Contrave. Orexigen [online], http://ir.orexigen.com/ phoenix. zhtml?c=207034&p=irol-newsArticle&ID= 1608571&highlight= (2011).
155. Ledford, H. Slim spoils for obesity drugs. Nature 468, 878 (2010).
156. Rothman, R. B. & Baumann, M. H. Appetite suppressants, cardiac valve disease and combination pharmacotherapy. Am. J. Ther. 16, 354-364 (2009).
157. Wilding, J., Van Gaal, L., Rissanen, A., Vercruysse, F. & Fitchet, M. A randomized double-blind placebo-controlled study of the long-term efficacy and safety of topiramate in the treatment of obese subjects. Int. J. Obes. 28, 1399-1410 (2004).
158. Bray, G. A. et al. A 6-month randomized, placebo-controlled, dose-ranging trial of topiramate for weight loss in obesity. Obes. Res. 11, 722-733 (2003).
159. Tonstad, S. et al. Efficacy and safety of topiramate in the treatment of obese subjects with essential hypertension. Am. J. Cardiol. 96, 243-251 (2005).
160. Gadde, K. M. et al. Effects of low-dose, controlled-release, phentermine plus topiramate combination on weight and associated comorbidities in overweight and obese adults (CONQUER): a randomised, placebo-controlled, phase 3 trial. Lancet 377, 1341-1352 (2011).
161. Allison, D. B. et al. Controlled-release phentermine/topiramate in severely obese adults: a randomized controlled trial (EQUIP). Obesity 20, 330-342 (2011).
162. Katz, A. Modulation of glucose transport in skeletal muscle by reactive oxygen species. J. Appl. Physiol. 102, 1671-1676 (2007).
163. Ritchie, R. H. & Delbridge, L. M. Cardiac hypertrophy, substrate utilization and metabolic remodelling: cause or effect? Clin. Exp. Pharmacol. Physiol. 33, 159-166 (2006).
164. Lopaschuk, G. D. & Jaswal, J. S. Energy metabolic phenotype of the cardiomyocyte during development, differentiation, and postnatal maturation. J. Cardiovasc. Pharmacol. 56, 130-140 (2010).
165. Augustus, A. S. et al. Loss of lipoprotein lipase-derived fatty acids leads to increased cardiac glucose metabolism and heart dysfunction. J. Biol. Chem. 281, 8716-8723 (2006).
166. Gupte, S. A. et al. Glucose-6-phosphate dehydrogenase-derived NADPH fuels superoxide production in the failing heart. J. Mol. Cell. Cardiol. 41, 340-349 (2006).
167. Gupte, R. S. et al. Upregulation of glucose-6-phosphate dehydrogenase and NAD(P)H oxidase activity increases oxidative stress in failing human heart. J. Card. Fail. 13, 497-506 (2007).
168. Stanley, W. C., Recchia, F. A. & Lopaschuk, G. D. Myocardial substrate metabolism in the normal and failing heart. Physiol. Rev. 85, 1093-1129 (2005).
169. Sharma, N. et al. High fructose diet increases mortality in hypertensive rats compared to a complex carbohydrate or high fat diet. Am. J. Hypertens. 20, 403-409 (2007).
170. Lee, C. et al. Fasting cycles retard growth of tumors and sensitize a range of cancer cell types to chemotherapy. Sci. Transl. Med. 4, 124ra127 (2012).
171. Lee, C. & Longo, V. D. Fasting vs dietary restriction in cellular protection and cancer treatment: from model organisms to patients. Oncogene 30, 3305-3316 (2011).
172. Raffaghello, L. et al. Fasting and differential chemotherapy protection in patients. Cell Cycle 9, 4474-4476 (2010).
173. Safdie, F. M. et al. Fasting and cancer treatment in humans: a case series report. Aging (Albany NY) 1, 988-1007 (2009).
174. Raffaghello, L. et al. Starvation-dependent differential stress resistance protects normal but not cancer cells against high-dose chemotherapy. Proc. Natl Acad. Sci. USA 105, 8215-8220 (2008).
175. Liao, C. Y., Rikke, B. A., Johnson, T. E., Diaz, V. & Nelson, J. F. Genetic variation in the murine lifespan response to dietary restriction: from life extension to life shortening. Aging Cell 9, 92-95 (2010).
176. Fontana, L., Klein, S. & Holloszy, J. O. Long-term low-protein, low-calorie diet and endurance exercise modulate metabolic factors associated with cancer risk. Am. J. Clin. Nutr. 84, 1456-1462 (2006).
177. Fontana, L., Klein, S. & Holloszy, J. O. Effects of long-term calorie restriction and endurance exercise on glucose tolerance, insulin action, and adipokine production. Age (Dordr.) 32, 97-108 (2010).
178. Fontana, L. et al. Calorie restriction or exercise: effects on coronary heart disease risk factors. A randomized, controlled trial. Am. J. Physiol. Endocrinol. Metab. 293, e197-e202 (2007).
179. Riordan, M. M. et al. The effects of caloric restriction-and exercise-induced weight loss on left ventricular diastolic function. Am. J. Physiol. Heart Circ. Physiol. 294, H1174-H1182 (2008).
180. Villareal, D. T. et al. Bone mineral density response to caloric restriction-induced weight loss or exercise-induced weight loss: a randomized controlled trial. Arch. Int. Med. 166, 2502-2510 (2006).
181. Villareal, D. T. et al. Reduced bone mineral density is not associated with significantly reduced bone quality in men and women practicing long-term calorie restriction with adequate nutrition. Aging Cell 10, 96-102 (2011).
182. MacDonald, L., Radler, M., Paolini, A. G. & Kent, S. Calorie restriction attenuates LPS-induced sickness behavior and shifts hypothalamic signaling pathways to an anti-inflammatory bias. Am. J. Physiol. Regul. Integr. Comp. Physiol. 301, R172-R184 (2011).
183. Milanski, M. et al. Saturated fatty acids produce an inflammatory response predominantly through the activation of TLR4 signaling in hypothalamus: implications for the pathogenesis of obesity. J. Neurosci. 29, 359-370 (2009).
184. Fleischman, A., Shoelson, S. E., Bernier, R. & Goldfine, A. B. Salsalate improves glycemia and inflammatory parameters in obese young adults. Diabetes Care 31, 289-294 (2008).
185. Baur, J. A. et al. Resveratrol improves health and survival of mice on a high-calorie diet. Nature 444, 337-342 (2006).
186. Lagouge, M. et al. Resveratrol improves mitochondrial function and protects against metabolic disease by activating SIRT1 and PGC-1α. Cell 127, 1109-1122 (2006).
187. Pearson, K. J. et al. Resveratrol delays age-related deterioration and mimics transcriptional aspects of dietary restriction without extending life span. Cell Metab. 8, 157-168 (2008).
188. Timmers, S. et al. Calorie restriction-like effects of 30 days of resveratrol supplementation on energy metabolism and metabolic profile in obese humans. Cell Metab. 14, 612-622 (2011).
189. Ganjam, G. K., Dimova, E. Y., Unterman, T. G. & Kietzmann, T. FoxO1 and HNF-4 are involved in regulation of hepatic glucokinase gene expression by resveratrol. J. Biol. Chem. 284, 30783-30797 (2009).
190. Bickenbach, K. A. et al. Resveratrol is an effective inducer of CArG-driven TNF-α gene therapy. Cancer Gene Ther. 15, 133-139 (2008).
191. Park, C. E. et al. Resveratrol stimulates glucose transport in C2C12 myotubes by activating AMP-activated protein kinase. Exp. Mol. Med. 39, 222-229 (2007).
192. Dasgupta, B. & Milbrandt, J. Resveratrol stimulates AMP kinase activity in neurons. Proc. Natl Acad. Sci. USA 104, 7217-7222 (2007).
193. Andrews, Z. B. et al. Ghrelin promotes and protects nigrostriatal
194. He, C. et al. Exercise-induced BCL2-regulated autophagy is required for muscle glucose homeostasis. Nature 481, 511-515 (2012).
195. Sakamoto, K., Goransson, O., Hardie, D. G. & Alessi, D. R. Activity of LKB1 and AMPK-related kinases in skeletal muscle: effects of contraction, phenformin, and AICAR. Am. J. Physiol. Endocrinol. Metab. 287, e310-e317 (2004).
196. Narkar, V. A. et al. AMPK and PPARδ agonists are exercise mimetics. Cell 134, 405-415 (2008).
197. Diano, S. et al. Ghrelin controls hippocampal spine synapse density and memory performance. Nature Neurosci. 9, 381-388 (2006).
198. Abizaid, A. et al. Ghrelin modulates the activity and synaptic input organization of midbrain dopamine neurons while promoting appetite. J. Clin. Invest. 116, 3229-3239 (2006).
199. Perry, M. L. et al. Leptin promotes dopamine transporter and tyrosine hydroxylase activity in the nucleus accumbens of Sprague-Dawley rats. J. Neurochem. 114, 666-674 (2010).
200. Opland, D. M., Leinninger, G. M. & Myers, M. G. Modulation of the mesolimbic dopamine system by leptin. Brain Res. 1350, 65-70 (2010).
201. Fulton, S. et al. Leptin regulation of the mesoaccumbens dopamine pathway. Neuron 51, 811-822 (2006).
202. Hommel, J. D. et al. Leptin receptor signaling in midbrain dopamine neurons regulates feeding. Neuron 51, 801-810 (2006).
203. Muller, A. P. et al. Exercise increases insulin signaling in the hippocampus: physiological effects and pharmacological impact of intracerebroventricular insulin administration in mice. Hippocampus 21, 1082-1092 (2011).
204. Greenfield, J. R. et al. Modulation of blood pressure by central melanocortinergic pathways. N. Engl. J. Med. 360, 44-52 (2009).
205. Greenfield, J. R. Melanocortin signalling and the regulation of blood pressure in human obesity. J. Neuroendocrinol. 23, 186-193 (2011).
206. Kolonin, M. G., Saha, P. K., Chan, L., Pasqualini, R. & Arap, W. Reversal of obesity by targeted ablation of adipose tissue. Nature Med. 10, 625-632 (2004).
207. Barnhart, K. F. et al. A peptidomimetic targeting white fat causes weight loss and improved insulin resistance in obese monkeys. Sci. Transl. Med. 3, 108ra112 (2011).
208. Lijnen, H. R., Frederix, L. & Van Hoef, B. Fumagillin reduces adipose tissue formation in murine models of nutritionally induced obesity. Obesity 18, 2241-2246 (2010).
209. Scroyen, I., Christiaens, V. & Lijnen, H. R. Effect of fumagillin on adipocyte differentiation and adipogenesis. Biochim. Biophys. Acta 1800, 425-429 (2010).
210. Kim, D. H., Woods, S. C. & Seeley, R. J. Peptide designed to elicit apoptosis in adipose tissue endothelium reduces food intake and body weight. Diabetes 59, 907-915 (2010).
211. Cannon, B. & Nedergaard, J. Brown adipose tissue: function and physiological significance. Physiol. Rev. 84, 277-359 (2004).
212. Richard, D. & Picard, F. Brown fat biology and thermogenesis. Frontiers Biosci. 16, 1233-1260 (2011).
213. Kim, E. B. et al. Genome sequencing reveals insights into physiology and longevity of the naked mole rat. Nature 479, 223-227 (2011).
214. Cypess, A. M. et al. Identification and importance of brown adipose tissue in adult humans. N. Engl. J. Med. 360, 1509-1517 (2009).
215. Ouellet, V. et al. Brown adipose tissue oxidative metabolism contributes to energy expenditure during acute cold exposure in humans. J. Clin. Invest. 122, 545-552 (2012).
216. Bartelt, A. et al. Brown adipose tissue activity controls triglyceride clearance. Nature Med. 17, 200-205 (2011).
217. Bostrom, P. et al. A PGC1-α-dependent myokine that drives brown-fat-like development of white fat and thermogenesis. Nature 481, 463-468 (2012).
218. Karelis, A. D. et al. The metabolically healthy but obese individual presents a favorable inflammation profile. J. Clin. Endocrinol. Metab. 90, 4145-4150 (2005).
219. Brochu, M. et al. What are the physical characteristics associated with a normal metabolic profile despite a high level of obesity in postmenopausal women? J. Clin. Endocrinol. Metab. 86, 1020-1025 (2001).
220. Arnlov, J., Ingelsson, E., Sundstrom, J. & Lind, L. Impact of body mass index and the metabolic syndrome on the risk of cardiovascular disease and death in middle-aged men. Circulation 121, 230-236 (2010).
221. Arnlov, J., Sundstrom, J., Ingelsson, E. & Lind, L. Impact of BMI and the metabolic syndrome on the risk of diabetes in middle-aged men. Diabetes Care 34, 61-65 (2011).
222. Appel, L. J. et al. Comparative effectiveness of weight-loss interventions in clinical practice. N. Engl. J. Med. 365, 1959-1968 (2011).
223. Wadden, T. A. et al. A two-year randomized trial of obesity treatment in primary care practice. N. Engl. J. Med. 365, 1969-1979 (2011).
224. Yaswen, L., Diehl, N., Brennan, M. B. & Hochgeschwender, U. Obesity in the mouse model of pro-opiomelanocortin deficiency responds to peripheral melanocortin. Nature Med. 5, 1066-1070 (1999).
225. Yen, T. T., Gill, A. M., Frigeri, L. G., Barsh, G. S. & Wolff, G. L. Obesity, diabetes, and neoplasia in yellow Avy/-mice: ectopic expression of the agouti gene. FASEB J. 8, 479-488 (1994).
226. Huszar, D. et al. Targeted disruption of the melanocortin-4 receptor results in obesity in mice. Cell 88, 131-141 (1997).
227. Butler, A. A. et al. A unique metabolic syndrome causes obesity in the melanocortin-3 receptor-deficient mouse. Endocrinology 141, 3518-3521 (2000).
228. Krude, H. et al. Severe early-onset obesity, adrenal insufficiency and red hair pigmentation caused by POMC mutations in humans. Nature Genet. 19, 155-157 (1998).
229. Clément, K. et al. Unexpected endocrine features and normal pigmentation in a young adult patient carrying a novel homozygous mutation in the POMC gene. J. Clin. Endocrinol. Metab. 93, 4955-4962 (2008).
230. Vaisse, C., Clement, K., Guy-Grand, B. & Froguel, P. A frameshift mutation in human MC4R is associated with a dominant form of obesity. Nature Genet. 20, 113-114 (1998).
231. Yeo, G. S. et al. A frameshift mutation in MC4R associated with dominantly inherited human obesity. Nature Genet. 20, 111-112 (1998).
232. Farooqi, I. S. et al. Dominant and recessive inheritance of morbid obesity associated with melanocortin 4 receptor deficiency. J. Clin. Invest. 106, 271-279 (2000).
233. Vaisse, C. et al. Melanocortin-4 receptor mutations are a frequent and heterogeneous cause of morbid obesity. J. Clin. Invest. 106, 253-262 (2000).
234. Farooqi, I. S. et al. Clinical spectrum of obesity and mutations in the melanocortin 4 receptor gene. N. Engl. J. Med. 348, 1085-1095 (2003).
235. Branson, R. et al. Binge eating as a major phenotype of melanocortin 4 receptor gene mutations. N. Engl. J. Med. 348, 1096-1103 (2003).
236. Fan, W. et al. The central melanocortin system can directly regulate serum insulin levels. Endocrinology 141, 3072-3079 (2000).
237. Wiedmer, P. et al. The HPA axis modulates the CNS melanocortin control of liver triacylglyceride metabolism. Physiol. Behav. 105, 791-799 (2011).
238. Perez-Tilve, D. et al. Melanocortin signaling in the CNS directly regulates circulating cholesterol. Nature Neurosci. 13, 877-882 (2010).
239. Vella, K. R. et al. NPY and MC4R signaling regulate thyroid hormone levels during fasting through both central and peripheral pathways. Cell Metab. 14, 780-790 (2011).
240. Preston, E. et al. Central neuropeptide Y infusion and melanocortin 4 receptor antagonism inhibit thyrotropic function by divergent pathways. Neuropeptides 45, 407-415 (2011).
241. Tong, Q., Ye, C. P., Jones, J. E., Elmquist, J. K. & Lowell, B. B. Synaptic release of GABA by AgRP neurons is required for normal regulation of energy balance. Nature Neurosci. 11, 998-1000 (2008).
242. Wu, Q. & Palmiter, R. D. GABAergic signaling by AgRP neurons prevents anorexia via a melanocortin-independent mechanism. Eur. J. Pharmacol. 660, 21-27 (2011).
243. Wu, Q., Howell, M. P., Cowley, M. A. & Palmiter, R. D. Starvation after AgRP neuron ablation is independent of melanocortin signaling. Proc. Natl Acad. Sci. USA 105, 2687-2692 (2008).
244. Grandison, L. & Guidotti, A. Stimulation of food intake by muscimol and β endorphin. Neuropharmacology 16, 533-536 (1977).
245. Kelly, J., Alheid, G. F., Newberg, A. & Grossman, S. P. GABA stimulation and blockade in the hypothalamus and midbrain: effects on feeding and locomotor activity. Pharmacol. Biochem. Behav. 7, 537-541 (1977).
246. Przewlocka, B., Stala, L. & Scheel-Kruger, J. Evidence that GABA in the nucleus dorsalis raphe induces stimulation of locomotor activity and eating behavior. Life Sci. 25, 937-945 (1979).
247. Kelly, J., Rothstein, J. & Grossman, S. P. GABA and hypothalamic feeding systems. I. Topographic analysis of the effects of microinjections of muscimol. Physiol. Behav. 23, 1123-1134 (1979).
248. Wu, Q., Clark, M. S. & Palmiter, R. D. Deciphering a neuronal circuit that mediates appetite. Nature 483, 594-597 (2012).
249. Kojima, M. et al. Ghrelin is a growth-hormone-releasing acylated peptide from stomach. Nature 402, 656-660 (1999).
250. Tschop, M., Smiley, D. L. & Heiman, M. L. Ghrelin induces adiposity in rodents. Nature 407, 908-913 (2000).
251. Cowley, M. A. et al. The distribution and mechanism of action of ghrelin in the CNS demonstrates a novel hypothalamic circuit regulating energy homeostasis. Neuron 37, 649-661 (2003).
252. Carlini, V. P. et al. Differential role of the hippocampus, amygdala, and dorsal raphe nucleus in regulating feeding, memory, and anxiety-like behavioral responses to ghrelin. Biochem. Biophys. Res. Commun. 313, 635-641 (2004).
253. Malik, S., McGlone, F., Bedrossian, D. & Dagher, A. Ghrelin modulates brain activity in areas that control appetitive behavior. Cell Metab. 7, 400-409 (2008).
254. Yang, Y., Atasoy, D., Su, H. H. & Sternson, S. M. Hunger states switch a flip-flop memory circuit via a synaptic AMPK-dependent positive feedback loop. Cell 146, 992-1003 (2011).
255. Dietrich, M. O. & Horvath, T. L. Synaptic plasticity of feeding circuits: hormones and hysteresis. Cell 146, 863-865 (2011).
256. i via AMPK in hypothalamic arcuate nucleus NPY neurons. Biochem. Biophys. Res. Commun. 366, 388-392 (2008).
257. Szczypka, M. S. et al. Dopamine production in the caudate putamen restores feeding in dopamine-deficient mice. Neuron 30, 819-828 (2001).
258. Szczypka, M. S. et al. Feeding behavior in dopamine-deficient mice. Proc. Natl Acad. Sci. USA 96, 12138-12143 (1999).
259. ob/ob mice. Nature Genet. 25, 102-104 (2000).
260. Morrison, C. D. Leptin signaling in brain: a link between nutrition and cognition? Biochim. Biophys. Acta 1792, 401-408 (2009).
261. Farooqi, I. S. et al. Leptin regulates striatal regions and human eating behavior. Science 317, 1355 (2007).
262. Batterham, R. L. et al. PYY modulation of cortical and hypothalamic brain areas predicts feeding behaviour in humans. Nature 450, 106-109 (2007).
263. Ren, H. et al. FoxO1 target Gpr17 activates AgRP neurons to regulate food intake. Cell 149, 1314-1326 (2012).
264. Atasoy, D., Betley, J. N., Su, H. H. & Sternson, S. M. Deconstruction of a neural circuit for hunger. Nature 11 July 2012 (doi:10.1038/nature11270).
265. Dietrich, M. O. et al. AgRP neurons regulate development of dopamine neuronal plasticity and nonfood-associated behaviors. Nature Neurosci. 24 June 2012 (doi:10.1038/nn.3147).